Blood Pressure Heart Failure Obesity 
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 trillion by 2050, according to two American Heart Association ( AHA ) presidential advisories published June 4 in the AHA journal Circulation.
Cardiometabolic Health Congress
NOVEMBER 14, 2024
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Ndumele provided an in-depth analysis of cardiac biomarkers and their role in cardiovascular risk prediction and heart failure (HF) management at the 19th Annual CMHC. In the U.S.,
Dr. Paddy Barrett
AUGUST 9, 2024
The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.
CardiacWire
AUGUST 14, 2024
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements – without the risk of muscle loss. blood pressure, pulse, glucose control, inflammation, lipid levels, and liver enzymes).
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2 of placebo-takers.
Cardiometabolic Health Congress
NOVEMBER 22, 2024
Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.
Cardiometabolic Health Congress
JULY 25, 2023
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Expert insights. Personalized for you.
105 
Let's personalize your content